Histogenics Announces Top-Line Results From Phase 3 Clinical Trial of NeoCart® in Patients With Knee Cartilage Damage
September 05, 2018 05:00 ET
|
Histogenics Corporation
‒ Phase 3 Clinical Trial of NeoCart Did Not Meet Primary Endpoint of a Statistically Significant Improvement in Pain and Function in a Dual Threshold Responder Analysis One Year After...
Histogenics Completes Enrollment for Phase 3 Clinical Trial of Neocart® to Treat Knee Cartilage Damage
June 27, 2017 16:01 ET
|
Histogenics Corporation
– On Track for Top-Line One Year Superiority Data and Potential BLA Filing in Third Quarter of 2018 – – Novel Tissue Implant Potentially Accelerates Recovery and Reduces Pain through Proprietary...